WLK heads into its August 4 earnings report with short interest rising sharply, analyst targets in retreat, and the stock down 6% on the week — a setup that concentrates attention on whether the next print can break a troubling trend.
The most striking development this week is the pace at which bearish positioning has built. Short interest climbed 10% over the past seven days to reach 4.1% of the free float — a 45% increase from where it stood a month ago. That kind of build-rate in the weeks before an earnings date signals genuine conviction among short sellers, not just passive drift. The ORTEX short score has ticked higher, now running at 56.2, up from 54.8 two weeks ago. Still, the borrow market is not signalling stress in either direction. Availability is ample — roughly 9 shares remain available to borrow for every one currently lent out — and cost to borrow has actually eased 20% this week to just 0.4%. Bears are building positions cheaply and without friction, which reinforces that this is a directional call on fundamentals rather than a technical squeeze play.
Options traders are not adding much urgency to the picture. The put/call ratio is running at 0.44, barely a third of a standard deviation above its 20-day mean. For a stock entering a binary event with this kind of short build, options positioning is remarkably calm — suggesting that downside hedging through derivatives has not yet caught up with the shift in short interest. The PCR's 52-week low sits at 0.32 and the high at an extreme 8.70, so the current reading is close to its most bullish historical extreme rather than reflecting pre-earnings defensiveness.
The Street is aligned in one direction only: lower. Every recent analyst move has been a target cut. Truist trimmed from $127 to $104 on July 20 while keeping a Buy. Morgan Stanley cut from $106 to $92 just weeks earlier. Bank of America, Mizuho, and Citi all reduced targets in late June, landing in the $85–$92 range. The mean price target now sits at $96 — still representing more than 30% upside to the $72.16 close — but that gap reflects a target-cutting cycle in progress rather than a bullish anchor. Capital Research and Management nearly doubled its position in the June quarter, adding 2.2 million shares, a notable institutional move that cuts against the prevailing analyst caution. At book value of 1.05x and EV/EBITDA of 6.8x, the valuation is lean, though the 30% forward earnings yield compressor over the past month shows the multiple is being squeezed by declining earnings estimates rather than price expansion.
The earnings history adds important context. The May 2026 print delivered a 13% single-day drop and extended to a 16% five-day loss — one of the sharper post-earnings selloffs in the chemical sector this year. The February print was far more benign on the day but dragged 18.5% lower over the following five sessions. Both episodes point to a stock where the damage tends to accumulate after the initial reaction, not simply on the announcement. Peers are moving in the same direction this week — OLN fell 7.7% and CE dropped 6.3% — suggesting broad commodity chemicals pressure rather than a WLK-specific story, though WLK has tracked the softer end of that peer range.
The factor picture is unambiguously mixed. EPS surprise ranks in the 97th percentile — Westlake has a strong history of beating estimates — but EPS momentum over both 30 and 90 days ranks in the bottom decile of the universe, at 6 and 20 respectively. That tension between a historically strong beat record and dramatically falling estimates is the core narrative heading into August 4: watch whether the beat reflex holds when the bar has been cut this aggressively.
See the live data behind this article on ORTEX.
Open WLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
